瑞替普酶静脉溶栓治疗急性心肌梗死临床探讨

Clinical Observation of Reteplase Intravenous Thrombolytic Therapy for Patients with Acute Myocardial Infarction

目的探讨瑞替普酶静脉溶栓治疗急性心肌梗死患者的临床效果。方法选取80例临床确诊为急性心肌梗死的患者,将其随机分为对照组、观察组,每组40例。分别采用尿激酶和瑞替普酶进行静脉溶栓治疗。观察两组患者的再通率、有效率、并发症发生率、死亡率。结果观察组的再通率(82.5%)明显优于对照组(67.5%,P<0.01),总有效率(92.5%)高于对照组(75.0%,P<0.05),观察组并发症发生率(7.5%)明显少于对照组(17.5%,P<0.01),死亡率均为7.5%,两组差异无统计学意义。结论瑞替普酶早期静脉溶栓治疗急性心肌梗死,能够改善患者预后,临床效果较好。

Objective To observe the clinical effect of reteplase intravenous thrombolytic therapy on patients with acute myocardial infarction. Methods 80 patients diagnosed with acute myocardial infarction clinically were randomly divided into the control group and the observation group with 40 patients in each. The control group were given intravenous thrombolytic therapy with urokinase and the observation group were given reteplase. And the recanalization rate, therapeutic effective rate, incidence of adverse reactions and mortality of the two groups of patients were observed. Results The recanalization rate of the observation group （82.5%） was significantly better than that （67.5%） of the control group （P〈0.01）; the total effective rate（92.5%） was higher than that （75.0%） of the control group （P〈0.05）; the incidence of complications of the observation group （7.5%） was significantly less than that （17.5%） of the control group （P〈0.01）; but the mortality rate of both groups was 7.5% with no difference. Conclusion The clinical effect of early reteplase intravenous thrombolytic therapy on patients with acute myocardial infarction is very satisfactory. It can im- prove the prognosis of the patients.